Our top pick for
Building a portfolio
Deciphera Pharmaceuticals, Inc is a biotechnology business based in the US. Deciphera Pharmaceuticals shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals employs 350 staff and has a trailing 12-month revenue of around USD$42.1 million.
|52-week range||USD$39.42 - USD$66.64|
|50-day moving average||USD$43.601|
|200-day moving average||USD$52.684|
|Wall St. target price||USD$75.73|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.312|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$42.1 million|
|Gross profit TTM||USD$-157,108,000|
|Return on assets TTM||-26.8%|
|Return on equity TTM||-48.89%|
|Market capitalisation||USD$2.6 billion|
TTM: trailing 12 months
There are currently 3.4 million Deciphera Pharmaceuticals shares held short by investors – that's known as Deciphera Pharmaceuticals's "short interest". This figure is 4.4% up from 3.3 million last month.
There are a few different ways that this level of interest in shorting Deciphera Pharmaceuticals shares can be evaluated.
Deciphera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Deciphera Pharmaceuticals shares currently shorted divided by the average quantity of Deciphera Pharmaceuticals shares traded daily (recently around 446971.91157347). Deciphera Pharmaceuticals's SIR currently stands at 7.69. In other words for every 100,000 Deciphera Pharmaceuticals shares traded daily on the market, roughly 7690 shares are currently held short.
However Deciphera Pharmaceuticals's short interest can also be evaluated against the total number of Deciphera Pharmaceuticals shares, or, against the total number of tradable Deciphera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Deciphera Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Deciphera Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.084% of the tradable shares (for every 100,000 tradable Deciphera Pharmaceuticals shares, roughly 84 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Deciphera Pharmaceuticals.
Find out more about how you can short Deciphera Pharmaceuticals stock.
We're not expecting Deciphera Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Deciphera Pharmaceuticals's shares have ranged in value from as little as $39.42 up to $66.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals's is 1.5094. This would suggest that Deciphera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.